7. SGRQ individual treatment effects versus placebo (six months)a.
| Rank (from class NWMA) | Effect vs placebo Class NWMA | Effect vs placebo NWMA no class | Rank (from class NWMA) | ||||||
| Class | Treatment (number daily doses) | Median | 95% CrI | Median | 95% CrI | Mean | Median | 95% CrI | Pr (best) |
| LABA | Form 12 (2) | ‐1.84 | (‐2.60 to ‐0.94) | ‐1.20 | (‐2.10 to ‐0.30) | 14.9 | 15 | (10 to 17) | 0.00 |
| Ind 300 (1) | ‐2.38 | (‐3.63 to ‐1.44) | ‐3.10 | (‐4.86 to ‐1.36) | 11.3 | 12 | (5 to 17) | 0.00 | |
| Ind 150 (1) | ‐2.75 | (‐3.95 to ‐1.85) | ‐3.67 | (‐4.76 to ‐2.58) | 8.7 | 8 | (3 to 16) | 0.01 | |
| Salm 50 (2) | ‐2.20 | (‐2.98 to ‐1.43) | ‐2.27 | (‐3.27 to ‐1.27) | 12.9 | 13 | (7 to 17) | 0.00 | |
| LAMA | Tio 5 (1) | ‐2.50 | (‐3.16 to ‐1.86) | ‐2.42 | (‐3.20 to ‐1.63) | 10.5 | 10 | (6 to 16) | 0.00 |
| Tio 18 (1) | ‐2.53 | (‐3.12 to ‐1.97) | ‐2.66 | (‐3.33 to ‐1.99) | 10.3 | 10 | (6 to 15) | 0.00 | |
| Acl 200 (2) | ‐2.66 | (‐4.04 to ‐1.70) | ‐3.79 | (‐6.14 to ‐1.45) | 9.1 | 9 | (2 to 16) | 0.01 | |
| Acl 400 (2) | ‐2.81 | (‐4.40 to ‐1.90) | ‐4.59 | (‐6.94 to ‐2.23) | 7.9 | 7 | (1 to 15) | 0.03 | |
| Gly 50 (1) | ‐2.63 | (‐3.42 to ‐1.94) | ‐2.83 | (‐3.74 to ‐1.91) | 9.5 | 9 | (5 to 15) | 0.00 | |
| ICS | Bud 400 (2) | ‐1.76 | (‐2.82 to ‐0.55) | ‐0.97 | (‐2.32 to 0.38) | 14.9 | 16 | (7 to 17) | 0.00 |
| Flut 500 (2) | ‐1.95 | (‐3.07 to ‐0.74) | ‐1.71 | (‐3.40 to ‐0.01) | 13.9 | 15 | (6 to 17) | 0.00 | |
| Mom 400 (2) | ‐2.28 | (‐3.51 to ‐1.19) | ‐2.77 | (‐4.47 to ‐1.09) | 11.9 | 13 | (5 to 17) | 0.00 | |
| LABA/ICS | Form‐bud 12/160 (2) | ‐4.04 | (‐4.91 to ‐3.15) | ‐3.85 | (‐4.99 to ‐2.70) | 2.6 | 2 | (1 to 6) | 0.29 |
| Form‐bud 12/320 (2) | ‐3.80 | (‐4.63 to ‐2.84) | ‐3.31 | (‐4.39 to ‐2.22) | 3.9 | 4 | (1 to 9) | 0.10 | |
| Form‐mom 12/200 (2) | ‐3.85 | (‐4.82 to ‐2.66) | ‐3.45 | (‐5.17 to ‐1.74) | 3.7 | 4 | (1 to 10) | 0.15 | |
| Form‐mom 12/400 (2) | ‐3.75 | (‐4.72 to ‐2.48) | ‐3.09 | (‐4.81 to ‐1.37) | 4.3 | 4 | (1 to 11) | 0.10 | |
| Salm‐flut 50/500 (2) | ‐4.05 | (‐4.97 to ‐3.18) | ‐4.36 | (‐5.60 to ‐3.12) | 2.6 | 2 | (1 to 6) | 0.31 | |
aFor effects versus placebo, smaller values indicate larger benefits of the active treatment; all doses are given in micrograms.
Crl = credible interval.
SGRQ = St George's Respiratory Questionnaire.
ICS = inhaled corticosteroid.
LABA = long‐acting beta2‐agonist.
LABA/ICS = long‐acting beta2‐agonist/inhaled corticosteroid.
LAMA = long‐acting antimuscarinic antagonist.
NWMA = network meta‐analysis.
Pr = probability.